alexa Peptide-based Delivery Of Oligonucleotides Studied By An In Vitro Model Of Blood-brain Barrier
ISSN 2472-1042

Pharmacoeconomics: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

11th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry
February 27-28, 2017 Amsterdam, Netherlands

Artita Srimanee, Jakob Regberg, Mattias Hallbrink and Ulo Langel
Stockholm University, Sweden
University of Tartu, Estonia
Posters & Accepted Abstracts: Pharmacoeconomics
DOI: 10.4172/2472-1042.C1.003
Glioblastoma multiforme (GBM) is an aggressive malignant brain tumor with poor prognosis after interventions. A blood-brain barrier (BBB) is a major obstacle to limit the efficacy of chemotherapy and block the passage of all large molecular drugs to the brain tumor. In order to improve the delivery of therapeutic agents particularly in gene-based therapy, a peptide-based delivery was proposed in the study. A series of novel peptides were designed for dual purposes, to enhance the penetration across the BBB and to specifically target the brain cancer cells. In the study, the BBB model was set up using Transwell™ plate which is composed of two compartments. Both represent the blood side (upper) and the brain side (lower) and they were cultured with the brain endothelial cells (bEnd.3) and glioma cell line (U87), respectively. The nanocomplexes of peptide and luciferase expressing plasmid DNA (pGL3) were formed and tested in an in vitro model of BBB. The luciferase transfection efficacy was measured in both cell lines and also WST- 1 cell viability assay was done to determine the toxicity of the complexes. PepFect 32 (PF32), a cell-penetrating peptide coupled to a targeting ligand angiopep-2, showed to be an efficient vector for pDNA delivery across the BBB model to target to glioma cells with no toxicity to both cell lines.

Artita Srimanee received her PhD in Pharmaceutical Chemistry and Phytochemistry from Faculty of Pharmacy, Mahidol University, Thailand in 2014. She joined the group of Professor Ülo Langel in the Department of Neurochemistry at Stockholm University, Sweden through a Student Exchange Program while doing her PhD in Thailand. Her research focuses on design, synthesis and modification of cell-penetrating peptides (CPPs) in order to deliver gene-based therapeutic agents to brain cancer cells. A setup in vitro model of the blood-brain barrier (BBB) using Transwell plate was designed and used to assess the transfection efficiency of nucleic acids such as siRNA and plasmid DNA delivered by CPPs. Moreover, she also studies transcytosis pathway of the nanoparticles across the BBB using brain endothelial cell line (bEnd.3) together with improvement the peptide-based vector using targeting modification strategy for the brain-targeted drug delivery.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version